Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. (Q52126724)

22 April 2018

title

Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. (English)

1 reference

22 April 2018

0 references

1 reference

2

Guy A Rouleau

1 reference

22 April 2018

3

Samarthji Lal

1 reference

22 April 2018

Chawki Benkelfat

11

object named as

Chawki Benkelfat

1 reference

22 April 2018

author name string

Ridha Joober

1

1 reference

22 April 2018

Michael Dixon

4

1 reference

22 April 2018

Gillian O'Driscoll

5

1 reference

22 April 2018

Roberta Palmour

6

1 reference

22 April 2018

Lawrence Annable

7

1 reference

22 April 2018

David Bloom

8

1 reference

22 April 2018

Pierre Lalonde

9

1 reference

22 April 2018

Alain Labelle

10

1 reference

22 April 2018

language of work or name

English

0 references

publication date

1 January 2002

1 reference

22 April 2018

number of pages

10

1 reference

inferred from page(s)

published in

Schizophrenia Research

1 reference

22 April 2018

volume

53

1 reference

22 April 2018

issue

3

1 reference

22 April 2018

page(s)

229-238

1 reference

22 April 2018

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

The distribution of manual asymmetry

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

The neuropsychological signature of schizophrenia: generalized or differential deficit?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Defining treatment refractoriness in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Premorbid asocial adjustment and prognosis in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Predicting haloperidol treatment response in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Haloperidol-induced changes in blink rates correlate with changes in BPRS score

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Neuropsychological risk indicators for schizophrenia: a review of family studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

The evolution of treatment resistance: biologic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Generalized cognitive deficits in schizophrenia: a study of first-episode patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Information processing and attentional functioning in the developmental course of schizophrenic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Familial schizophrenia and treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Memory deficit and long-term outcome in schizophrenia: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Neuropsychology of schizophrenia according to Kraepelin: Disorders of volition and executive functioning

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

MRI correlates of treatment response in first episode psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

Contributions of clinical neuropsychology to the study of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900279-1

7 January 2021

10.1016/S0920-9964(01)00279-1

Identifiers

DOI

1 reference

22 April 2018

1 reference

22 April 2018